Friday, January 10, 2020

China-based I-Mab To Make U.S. Trading Debut Next Week

I-Mab is a clinical stage biopharmaceutical company developing novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

from RTT - Biotech https://ift.tt/37QVoDz
via IFTTT

No comments:

Post a Comment